| Literature DB >> 30819108 |
Nerissa L Hearn1, Aaron S Coleman1, Vincent Ho1, Christine L Chiu2, Joanne M Lind1,3.
Abstract
BACKGROUND: Altered epigenetic profiles are a feature of intestinal diseases, including ulcerative colitis and Crohn's disease. DNA methylation studies in these diseases have utilised intestinal mucosal tissue or blood which can be difficult to collect, particularly for large-scale research studies. Saliva is an attractive alternative for epigenetic studies as it is easy to collect and provides high quality methylation profiles. The aim of the study was to determine the utility of saliva as an alternative for DNA methylation studies of intestinal disorders.Entities:
Keywords: DNA methylation; Intestinal mucosal; Saliva
Mesh:
Year: 2019 PMID: 30819108 PMCID: PMC6394071 DOI: 10.1186/s12864-019-5553-0
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Clinical and demographical characteristics of individuals
| Patient | Age range | BMI | Ethnicity | Smoking Status | Reason for endoscopy | Medications |
|---|---|---|---|---|---|---|
| One | 65–74 | 30.0 | Caucasian | Quit | Difficulty swallowing | Somac, Warfarin |
| Two | 65–74 | 33.6 | Caucasian | Never | Epigastric pain | |
| Three | 65–74 | 39.9 | Caucasian | Never | Epigastric pain | Nexium |
| Four | 45–54 | 28.4 | Caucasian | Quit | Oesophageal reflux | Somac |
| Five | 18–25 | 25.4 | Caucasian | Never | Oesophageal reflux | Nexium, Motilium, Mezavart |
| Six | 45–54 | 30.1 | Caucasian | Never | Routine follow up for coeliac disease | |
| Seven | 35–44 | 26.3 | Caucasian | Quit | Routine follow up for coeliac disease | |
| Eight | 55–64 | 24.3 | Caucasian | Never | Routine follow up for coeliac disease | |
| Nine | 65–74 | 29.0 | Caucasian | Quit | Routine follow up for coeliac disease | |
| Ten | 18–25 | 17.8 | Caucasian | Never | Routine follow up for coeliac disease |
Fig. 1Data clustering and comparison between saliva and tissue DNA methylation profiles. a) Hierarchical clustering based on correlation distances of methylation profiles in 20 samples – intestinal mucosa and saliva samples from 10 individuals; b) Pearson correlation coefficients for methylation levels of saliva vs tissue for each of the CpG sites (positive correlations in boxed area with statistically significant correlations (adjusted P < 0.05) shown in red bars); c) The distribution of cg-probes plotted against the difference in methylation expressed as Δβ-values
Correlation of average DNA methylation across all CpG sites between saliva and intestinal mucosa within an individual
| Participant | r-value | Confidence Interval | |
|---|---|---|---|
| One | 0.927 | 0.926–0.927 | |
| Two | 0.950 | 0.950–0.951 | |
| Three | 0.921 | 0.920–0.921 | |
| Four | 0.939 | 0.938–0.939 | |
| Five | 0.947 | 0.946–0.947 | |
| Six | 0.928 | 0.928–0.929 | |
| Seven | 0.922 | 0.922–0.923 | |
| Eight | 0.924 | 0.923–0.924 | |
| Nine | 0.930 | 0.930–0.930 | |
| Ten | 0.935 | 0.935–0.936 |
Fig. 2Scatter plot of average DNA methylation beta values for 4000 random CpG sites between intestinal and saliva samples. Line represents the line of best fit
GO terms for differentially methylated genes between intestinal mucosa and saliva samples
| GO No. | GO Term | Count | Benjamini | |
|---|---|---|---|---|
| GO:0007156 | homophilic cell adhesion via plasma membrane adhesion molecules | 23/154 | ||
| GO:0098742 | cell-cell adhesion via plasma-membrane adhesion molecules | 24/221 | ||
| GO:0005509 | calcium ion binding | 33/684 | ||
| GO:0098609 | cell-cell adhesion | 43/1124 | ||
| GO:0007155 | cell adhesion | 53/1656 | ||
| GO:0022610 | biological adhesion | 53/1662 |
P value based on number of differentially expressed genes
Count is the number of genes within the test set over the total of number of genes within the GO term
Pathway analysis for differentially methylated genes between intestinal mucosa and saliva samples
| Pathway | Count | Benjamini | ||
|---|---|---|---|---|
| hsa04371 | Apelin signalling pathway | 5/137 | 0.01 | |
| hsa04810 | Regulation of actin cytoskeleton | 6/211 | 0.01 | |
| hsa05202 | Transcriptional misregulation in cancer | 6/174 | 0.01 | |
| hsa01100 | Metabolic pathways | 11/1241 | 0.01 | |
| hsa04022 | cGMP-PKG signalling pathway | 5/162 | 0.01 | |
| hsa04070 | Phosphatidylinositol signalling system | 4/97 | 0.01 | |
| hsa04144 | Endocytosis | 6/257 | 0.01 | |
| hsa04666 | Fc gamma R-mediated phagocytosis | 4/90 | 0.01 | |
| hsa04621 | NOD-like receptor signalling pathway | 4/158 | 0.01 | |
| hsa04020 | Calcium signalling pathway | 5/180 | 0.01 | |
| hsa04915 | Estrogen signalling pathway | 4/98 | 0.02 | |
| hsa04724 | Glutamatergic synapse | 4/114 | 0.03 | |
| hsa04662 | B cell receptor signalling pathway | 3/70 | 0.03 | |
| hsa05132 | Salmonella infection | 3/85 | 0.03 | |
| hsa04062 | Chemokine signalling pathway | 4/182 | 0.04 | |
| hsa04921 | Oxytocin signalling pathway | 4/152 | 0.04 |
P value based on number of differentially expressed genes
Count is the number of genes within the test set over the total of number of genes within the GO term